About Cellanome
Cellanome is a company based in Palo Alto (United States) founded in 2020 by Mostafa Ronaghi. Cellanome has raised $118.65 million across 3 funding rounds. Cellanome offers products and services including Automated Platform and Live Cell Assays. Cellanome operates in a competitive market with competitors including Cellworks, Tessera Therapeutics, Phase Genomics, Genuity Science and ICarbonX, among others.
- Headquarter Palo Alto, United States
- Founders Mostafa Ronaghi
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$118.65 M (USD)
in 3 rounds
-
Latest Funding Round
$75.93 M (USD), Series B
Dec 23, 2025
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cellanome
Cellanome offers a comprehensive portfolio of products and services, including Automated Platform and Live Cell Assays.
Enables detailed study of cell behaviors and interactions at scale.
Facilitates iterative assays linking cell responses to perturbations.
People of Cellanome
Unlock access to complete
Unlock access to complete
Funding Insights of Cellanome
Cellanome has successfully raised a total of $118.65M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $75.93 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Cellanome
Investment portfolio details for Cellanome
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cellanome
Detailed financials for Cellanome
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cellanome Comparisons
Peer comparison for Cellanome
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cellanome
Cellanome operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cellworks, Tessera Therapeutics, Phase Genomics, Genuity Science and ICarbonX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biosimulation platform developed for therapeutic design in life sciences.
|
|
| Locked | Locked | Locked |
New genome engineering technology is provided for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Laboratory and computational services for DNA proximity analysis are provided.
|
|
| Locked | Locked | Locked |
AI-based omics data analysis solutions are provided to researchers.
|
|
| Locked | Locked | Locked |
Bioinformatics platforms are provided for health management and drug development.
|
|
| Locked | Locked | Locked |
Bioinformatics tools for genome sequencing data analysis are provided.
|
Detailed competitors of Cellanome
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cellanome
Complete news archive for Cellanome
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellanome
Cellanome was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Cellanome is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Cellanome is a funded company, having raised a total of $118.65M across 3 funding rounds to date.
Cellanome was founded in 2020 and is headquartered in Palo Alto, United States. A multi-omics platform is provided by the company for researchers, integrating synthetic biology and informatics approaches. Operations focus on handling omic data to support scientific analysis in the biotechnology sector. Services enable data processing and integration across various omics disciplines.
Cellanome's top competitors include Tessera Therapeutics, Phase Genomics and Cellworks.
Cellanome offers Automated Platform and Live Cell Assays.